Nazim Benzerdjeb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4264874/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study. Annals of Surgical Oncology, 2022, 29, 2104-2113.	0.7	14
2	5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 23-29.	1.4	5
3	Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 765-772.	1.4	8
4	Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology, 2021, 157, 122-129.	0.3	28
5	Oropharyngeal squamous cell carcinoma: p16/p53 immunohistochemistry as a strong predictor of HPV tumour status. Histopathology, 2021, 79, 381-390.	1.6	16
6	Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 927-936.	1.4	3
7	Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncology, 2021, 119, 105368.	0.8	15
8	Functional outcomes of soft palate free flap reconstruction following oropharyngeal cancer surgery. European Journal of Surgical Oncology, 2021, 47, 2265-2271.	0.5	7
9	Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease?. European Journal of Surgical Oncology, 2020, 46, 582-589.	0.5	17
10	Poorly differentiated neuroendocrine carcinoma of the head and neck: human papillomavirus tumour status/p16 status and impact on overall survival. Histopathology, 2020, 76, 581-591.	1.6	8
11	Risk of Omental Metastases in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases. Diseases of the Colon and Rectum, 2020, 63, 1251-1256.	0.7	6
12	Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology, 2020, 77, 548-559.	1.6	26
13	The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising From Various Primary Tumors. Annals of Surgical Oncology, 2020, 27, 2985-2996.	0.7	37
14	Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study. European Journal of Surgical Oncology, 2019, 45, 2398-2404.	0.5	27
15	GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors?. Pathology International, 2017, 67, 32-36.	0.6	11
16	Primary cardiac B cell lymphoma: Manifestation of Felty's syndrome or TNFα antagonist. Pathology Research and Practice, 2016, 212, 1191-1193.	1.0	1
17	Digital holographic microscopy as screening tool for cervical cancer preliminary study. Cancer Cytopathology, 2016, 124, 573-580.	1.4	20